Services on Demand
- Similars in SciELO
Print version ISSN 1679-4508
Einstein (São Paulo) vol.10 no.2 São Paulo Apr./June 2012
Claudia Cristina Ferreiro-BarrosI; Eduardo Kinio SugawaraII; Livia Rentas SanchesII
IInstituto do Cérebro InCe, Hospital Israelita Albert Einstein HIAE, São Paulo (SP), Brazil.
IIClinical Laboratory / Special Chemistry, Hospital Israelita Albert Einstein HIAE, São Paulo (SP), Brazil.
OBJECTIVE: To establish a routine for the extraction of the total levels of CoQ10 in human plasma through the Ultra High Performance Liquid Chromatography (UHPLC).
METHODS: Two extraction protocols were tested: a) methanol: hexane and b) 1-propanol. The following parameters were analyzed: extraction temperature (19ºC and 4ºC), extraction tubes (glass and polypropylene), and surfactants (SDS, Triton X-100, Tween-20) at different concentrations, i.e., 1%, 3%, 5% and 10%.
RESULTS: The results showed that the method of extraction of CoQ10 in a sample of human plasma at 4ºC, using solvents methanol: hexane (85:15, v/v) in the presence of surfactant Tween-20 at 3% and polypropylene tubes showed better efficiency and reproducibility when compared to the method with 1-propanol.
CONCLUSION: By the analyses performed, it was possible to observe that the addition of the surfactant Tween-20 promoted an increase in the recovery of CoQ10 by the methanol:hexane extraction method. This method showed good reproducibility, with a low coefficient of variation and high sensitivity, since CoQ10 was detected in samples of plasma of a control individual using a UV-type detector. The use of UHPLC equipment allowed a total analysis with total run time of 3.5 minutes, enabling the rapid achievement of results, considered mandatory for laboratory routines.
Keywords: Coenzymes; Surfactants; Chromatography, liquid
Coenzyme Q10 (CoQ10), also known as ubiquinone, is a lipid molecule essential for aerobic organisms. It participates in the production of ATP through the oxidative phosphorylation process by transferring electrons from respiratory complexes I and II to complex III in the respiratory chain, located in the inner mitochondrial membrane. Additionally, CoQ10 participates in many other vital functions within the cell: it acts as an antioxidant of lipoproteins and cell membranes; it is required for the biosynthesis of pyrimidine affecting replication and repair of cellular DNA; it modulates the process of apoptosis through the regulation of the membrane transition pores, and aids in maintenance of body temperature resulting from its function in uncoupling proteins(1).
CoQ10 is composed of a ring of benzoquinone associated with a polyprenyl chain derived from the mevalonate pathway, the same synthesis route of cholesterol. The size of this polyprenyl chain varies among organisms; the human species has 10 repetitions (CoQ10), while mice have 9 (CoQ9), and Saccharomyces cerevisiae have 6 (CoQ6).
The endogenous synthesis of CoQ10 occurs in the mitochondria(1) and it is expressed in all tissues, but in greater concentration in the heart, kidneys, liver and muscles, since they are organs that require a greater quantity of energy (ATP) for their function, and decrease their expression during the process of cellular aging(2).
Clinically, patients with a CoQ10 deficiency are very heterogeneous, present variable phenotypes with neurological commitment in most cases(3). Therefore, some subtypes of clinical presentation seem to be more common: (1) encephalomyopathy, with mitochondrial myopathy and recurring myoglobinuria(4); (2) multisystem involvement in childhood; (3) Leigh syndrome; (4) myopathic form(5); (5) ataxic form, probably the most common among the five forms(6); (6) steroid-resistant nephrotic syndrome(7). Its association with other clinical phenotypes, such as seizures, muscle weakness, mental retardation, ophthalmoplegia, peripheral neuropathy, pyramidal signs and scoliosis is quite frequent. Hypergonadotrophic hypogonadism seems to be more common in patients with late onset of the disease(8).
The primary deficiency of CoQ10 is autosomal recessive and is included in the group of mitochondrial diseases. It is caused by a defect in the biosynthetic route of ubiquinone which is not yet completely elucidated(6). Among the mitochondrial diseases described, to date, CoQ10 deficiency is the only one that has chances of effective treatment through the exogenous CoQ10 administration(9).
Much of what is known about the biosynthesis of coenzyme Q comes from studies carried out with Escherichia coli and S. cerevisiae(10). There are at least a dozen genes named COQ1, COQ2, COQ3... COQ10 in Saccharomyces cerevisiae, necessary for the respiratory function of coenzyme Q(10-13).
In the human species, patients were described with mutations in genes COQ2, COQ4, COQ6, COQ8, COQ9, PDSS1 and PDSS2(14-20).
The secondary deficiency in the metabolism of CoQ10 was discussed in the pathophysiology of myopathy by statins, toxicity by anthracyclin and Parkinson's disease, but the relative contribution of CoQ10 in triggering these diseases is still unknown(21,22).
However, supplementation with CoQ10 is amply recommended at high doses (30mg/kg in children and at least 600mg daily in adults) for all patients with mitochondrial diseases, since it is a supplement devoid of side effects and it brings many benefits to cellular metabolism(23,24). Since it is lipophilic, CoQ10 is transported in circulation by particles of lipoproteins, and its concentration in the plasma has been correlated with the total levels of cholesterol, especially LDL, in patients who take statins(25,26).
Considering this effective possibility of treatment, interest in determining the levels of CoQ10 in the plasma and other types of cells or tissues were the target of various studies. The diagnosis of CoQ10 deficiency is performed through the analysis of the enzymatic activity of mitochondrial complexes I+II and II+III(1), as well as by quantification of the total levels of the enzyme directly in the muscle or fibroblasts. The levels of CoQ10 determined in the blood are not used for diagnosis, since CoQ10 is present in certain foods and is absorbed through the diet. However, it is used for therapeutic monitoring in patients with confirmed deficiency of the coenzyme.
There are various methods described in scientific literature for the quantification of CoQ10 in plasma, cells and tissues. The use of reverse phase high performance liquid chromatography (HPLC) equipment coupled with electrochemical or ultraviolet (UV)-type detectors is very frequent. Currently, most of the methods involve the preparation of the sample using a single stage of dilution with 1-propanol, followed by the direct injection of the sample into an HPLC system(27,28). However, this method is more commonly used in the electrochemical-type detector that displays greater sensitivity, allowing the detection of minimal concentrations of CoQ10. Due to the lower level of sensitivity of ultraviolet detectors, their use requires a more elaborate sample processing, with extraction stages using organic solvents such as hexane(29,30), hexane/methanol(31,32) or ethanol(33), followed by the concentration of the sample in order to then inject it into the HPLC system.
In this study, two CoQ10 extraction methods in human plasma were tested: methanol:hexane, and 1-propanol, both with UV detection. In the attempt to improve the methods of CoQ10 extraction by UV detection, the addition of some surfactants such as SDS (sodium dodecyl sulfate), Triton X-100 and Tween-20 was tested as to the possibility of obtaining a better recovery at the end of the extraction process. Other variables that may directly influence the result of CoQ10 quantification were also studied: temperature (4°C and 19°C) and types of tubes (glass and polypropylene).
To establish a routine for extraction of the total levels of CoQ10 in human plasma through the ultra high performance liquid chromatography (UHPLC) analysis.
Reagents and Solvents
Chromatographic grade solvents methanol, hexane and 1-propanol were obtained from Merck (Darmstadt, Germany) and Sigma-Aldrich (Missouri, USA), respectively. Reagents such as SDS (sodium dodecyl sulfate), Triton X-100 and CoQ10 standard (> 98% purity) were obtained from Sigma-Aldrich (Missouri, USA) and Tween 20 was obtained from Amresco (Solon, USA). Human albumin solution at 20% was provided by Grifols Brasil Ltda.
The standard solution of CoQ10 was prepared at the concentration of 1mg/mL using 1-propanol as dilution solvent, and storing it at -20°C protected from light.
For initial optimization and standardization studies of the CoQ10 extraction process, we used a 4% human albumin solution with the objective of simulating plasma samples, which then received the addition of the standard solution of CoQ10 resulting in the final concentration of 1000mg/mL. After definition of the best method for extraction, the blood collection protocol was followed as described below.
Samples of blood were collected from the same control individual by peripheral venous puncture into glass tubes containing anticoagulant citric acid, sodium citrate and dextrose, and maintained at 4°C. The plasma was obtained after centrifugation at 894.2g for 10 minutes at 4°C, transferred to Eppendorf-type tubes and stocked at -80°C for further analysis. Sample collection was performed after obtaining the signature on the informed consent form approved by the Research Ethics Committee of the Hospital Israelita Albert Einstein (No.10/1465).
Methods for extraction of CoQ10
CoQ10 extraction with methanol:hexane
The initial protocol was used(34), with the following modifications: 700mL of plasma, 100mL of detergents (SDS, Triton X-100 and Tween-20) at concentrations of 1%, 3%, 5% and 10% separately, 1400mL of methanol and 1500mL of hexane were added to a polypropylene tube and a glass tube. The samples were submitted to mechanical shaking for one minute and centrifuged at 1752.8g for 10 minutes at 10°C. The supernatants were transferred to a new tube and evaporated without heating under a flow of nitrogen for 20 minutes. Next, the residues were resuspended in 60mL of mobile phase of methanol:hexane (85:15, v/v), homogenized under vortex mechanical shaking for 15 seconds and orbital shaking for 15 minutes. For the chromatographic analysis, 20mL were used. Extractions were performed in triplicate at 19°C (controlled temperature) and at 4°C (ice bath).
CoQ10 extraction with 1-propanol
The initial protocol was used(27) with the following modifications: 700mL of plasma, 100mL of detergents (SDS, Triton X-100 and Tween 20) at the concentrations of 1%, 3%, 5% and 10% separately, 1400mL of 1-propanol were added to a polypropylene tube and a glass tube. The samples were submitted to shaking for one minute and were centrifuged at 894.2g for 10 minutes at 10°C, then transferred to an "amber vial" with the help of a filtrating unit with 0.22mm, 13mm. The chromatographic analysis was performed by means of a 20mL injection of the sample. The extractions were performed in triplicate at 19°C (controlled temperature) and at 4°C (ice bath).
Chromatographic analysis and detection of CoQ10
The equipment used for Ultra High Performance Liquid Chromatography (UHPLC) was HP1290 (Hewlett-Packard) constituted by an automatic sampler, binary pump, and UV detector with variable wavelength. The detection was made at 275nm. For the chromatographic separation, an analytical column was used, Zorbax Eclipsy C18® (50 x 2.1mm, 1.8µm), with an equivalent guard column, both obtained from Hewlett-Packard and maintained at 45°C during the analysis. The CoQ10 displayed a retention time of 1.5 minutes and the total time of chromatographic analysis was 3.5 minutes. The mobile phase used was methanol-hexane (85:15; v/v) with a flow rate of 0.45mL/min.
Establishment of the CoQ10 extraction protocol
For the establishment of the CoQ10 extraction protocol, initially performed were tests using 4% human albumin solution with added CoQ10 solution of 1000mg/mL. The extraction methods methanol:hexane and 1-propanol were tested in the presence and absence of surfactants such as SDS (anionic), Triton X-100 (non-ionic) and Tween-20 (non-ionic) at concentrations of 1%, 3%, 5% and 10%, at 4°C and 19°C. The first results indicated that the extraction method using methanol:hexane in the presence of the surfactants Triton X-100 and Tween-20 showed better rates of CoQ10 recovery, while with the use of SDS, the reproducibility and efficiency were much lower (data not shown).
The same extraction protocol used in the tests with CoQ10 added to albumin was applied to samples of plasma from control individuals without the addition of CoQ10 to verify the reproducibility of the method in real samples. The samples were analyzed as to temperature of extraction (controlled at 19°C and at 4°C, ice bath) and as to the composition of the tubes used for the extraction (polypropylene and glass), as per table 1.
The results demonstrate that the extractions performed in real samples of plasma presented a similar response as that shown with a solution of albumin in which the use of the detergent Tween-20 at 3%, at 4°C, using methanol:hexane resulted in the best response obtained for the detection of CoQ10 (Figure 1). In addition to presenting the best recovery, there was also good reproducibility between the replicates with a CV (coefficient of variation) of 4.3%. Thus, the option of using a surfactant such as Tween-20 resulted in an improvement (51.2%) in efficiency.
The chromatograms demonstrate the chromatographic quality obtained with the mobile phase composed of methanol:hexane (85:15, v/v) with a flow of 0.45mL/min. (Figure 2). The retention time of CoQ10 was 1.45 minutes and the peak purity (99%) was obtained through the analysis of its spectrum (ChemStation, Agilent).
The application of chromatographic techniques has been widely used in studies of enzymatic determination and pharmacokinetics for therapeutic monitoring. Recently, the interest in determining the levels of CoQ10 in plasma and other types of cells or tissues has been the target of various studies, given the possibility of effective treatment in neurological patients or those with metabolic diseases through the oral supplementation(35).
CoQ10 is present in circulating plasma associated with lipoproteins, and its concentration is directly related to the concentration of cholesterol present in the plasma(36). Due to this characteristic binding of CoQ10 to lipophilic molecules, we chose to use surfactants as aids in the extraction process with the intent of breaking this type of bond and thus increasing the levels of detection of the coenzyme. Some authors demonstrated that the action of SDS in plasma significantly increases the recovery of CoQ10 after the extraction process(37). Conversely, the effect of Triton X-100 on the solubilization of membranes was observed both in proteins and in lipids(38). Indeed, when initiating the first experiments, low rates of CoQ10 were attained without the addition of surfactants during the process of extraction, observed by the small chromatographic peak area (mUA).
In this study, the best results were achieved with the methanol:hexane extraction method when compared to 1-propanol. Some authors have used 1-propanol as a solvent for precipitation of proteins due to its greater lipophilic character, but the success of this technique only occurs when used in electrochemical-type detectors, since they are more sensitive than what was used in this study (UV). This occurs because this technique does not allow the concentration of the sample in the process of extraction, and the addition of 1-propanol merely acts by precipitating the proteins and diluting the sample, making it more difficult to quantify CoQ10 with the use of UV detectors. It was also observed that the use of surfactants Triton X-100 and Tween-20 resulted in better rates of recovery of CoQ10, while the use of SDS showed lower reproducibility and efficiency. Additionally, even when used at low concentrations, SDS promoted the formation of a "cloud point" that hindered the separation of the organic and aqueous phases.
When the established protocol using the human albumin solution was applied for the extraction of CoQ10 in real samples of plasma, the response was similar to that with the use of surfactant Tween 20 at 3%, at 4°C in methanol:hexane, resulting in a better recovery, good reproducibility among the replicates, a CV of 4.3%, and an increase of 51.2% in efficiency of the extraction process.
Temperature is also a relevant parameter to be evaluated when the substance studied is an enzyme, which since it is thermolabile, may easily suffer denaturation at higher temperatures.
The best results of this study showed that the control of the temperature (4°C) is of vital importance during the extraction process. It was also noted that there was better separation of the organic and aqueous phases when polypropylene tubes were used, contributing, in fact, to an improvement in the efficiency of the extraction.
By the analyses performed, it was possible to observe that the addition of the surfactant Tween-20 promoted an increase in the recovery of CoQ10 by the methanol:hexane extraction method. This method showed good reproducibility, with a low CV and high sensitivity, since CoQ10 was detected in samples of plasma of a control individual using a UV-type detector.
The use of UHPLC equipment allowed a total analysis with total run time of 3.5 minutes, enabling the rapid achievement of results, considered mandatory for laboratory routines.
Since this stage of method optimization was concluded, this extraction protocol is in the validation phase which will allow its applicability for future clinical tests with a guarantee of reliable results.
The authors thank Dr. Lionel F. Gamarra, from the Instituto do Cérebro, for the help at the beginning of the study, Marta J. Diniz for her technical laboratory support, Dr. Anna Carla Goldberg for allowing the development of this project at the Centro de Pesquisa Experimental do Hospital Israelita Albert Einstein, and Dr. Edson Amaro Júnior for the scientific support. This work was supported by FAPESP 10/51924-0.
1. Rahman S, Clarke C., Hirano M. 176th ENMC International Workshop: Diagnosis and treatment of coenzyme Q10 deficiency. Neuromus Disord. 2012;22(1):76-86. [ Links ]
2. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. 2004;1660(1-2):171-99. Review. [ Links ]
3. Quinzii CM, DiMauro S, Hirano M. Human coenzyme Q10 deficiency. Neurochem Res. 2007;32(4-5):723-7. [ Links ]
4. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989; 86(7):2379-82. [ Links ]
5. Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, ET al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001;56(7):849-55. [ Links ]
6. Montero R, Pineda M, Aracil A, Vilaseca MA, Briones P, Sánchez-Alcázar JA, ET al. Clinical, biochemical and molecular aspects of cerebellar ataxia and Coenzyme Q10 deficiency. Cerebellum. 2007;6(2):118-22. [ Links ]
7. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, et al.Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005;65(4):606-8. [ Links ]
8. Gironi M, Lamperti C, Nemni R, Moggio M, Comi G, Guerini FR, et al. Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency. Neurology. 2004;62(5):818-20. [ Links ]
9. Lagier-Tourenne C, Tazir M, López LC, Quinzii CM, Assoum M, Drouot N, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet. 2008;82(3):661-72. [ Links ]
10. Gin P, Clarke CF. Genetic evidence for a multi-subunit complex in coenzyme Q biosynthesis in yeast and the role of the Coq1 hexaprenyl diphosphate synthase. J Biol Chem. 2005;280(4):2676-81. [ Links ]
11. Tzagoloff A, Dieckmann CL. PET genes of Saccharomyces cerevisiae. Microbiol Rev. 1990;54(3):211-25. [ Links ]
12. Johnson A, Gin P, Marbois BN, Hsieh EJ, Wu M, Barros MH, et al. COQ9, a new gene required for the biosynthesis of coenzyme Q in Saccharomyces cerevisiae. J Biol Chem. 2005;280(36):31397-404. [ Links ]
13. Barros MH, Johnson A, Gin P, Marbois BN, Clarke CF, Tzagoloff A. The Saccharomyces cerevisiae COQ10 gene encodes a START domain protein required for function of coenzyme Q in respiration. Biol Chem. 2005;280(52): 42627-35. [ Links ]
14. Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006;78(2):345-9. [ Links ]
15. Salviati L, Trevisson E, Rodriguez Hernandez MA, Casarin A, Pertegato V, Doimo M, et al. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. J Med Genet. 2012;49(3):187-91. [ Links ]
16. Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest. 2011;121(5):2013-24. [ Links ]
17. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, Lombes A, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet. 2008;82(3):623-30. [ Links ]
18. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, López LC, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet. 2009;84(5):558-66. [ Links ]
19. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest. 2007;117(3):765-72. [ Links ]
20. López LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006; 79(6):1125-9. [ Links ]
21. Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005; 62(11):1709-12. [ Links ]
22. Molyneux SL, Young JM, Florkowski CM, Lever M, George PM. Coenzyme q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008;29(2):71-82. [ Links ]
23. Ernster, L., Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271(1):195-204. [ Links ]
24. Dimauro S, Rustin P. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta. 2009;1792(12):1159-67. [ Links ]
25. Kaikkonen J, Nyyssönen K, Salonen JT. Measurement and stability of plasma reduced, oxidized and total coenzyme Q10 in humans. Scand J Clin Lab Invest. 1999;59(6):457-66. [ Links ]
26. Edlund PO. Determination of coenzyme Q10, alpha-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with coulometric and ultraviolet detection. J Chromatogr. 1988;425(1):87-97. [ Links ]
27. Tang PH, Miles MV, DeGrauw A, Hershey A, Pesce A.HPLC analysis of reduced and oxidized coenzyme Q(10) in human plasma. Clin Chem. 2001;47(2):256-65. [ Links ]
28. Littarru GP, Mosca F, Fattorini D, Bompadre S, Battino M. Assay of coenzyme Q10 in plasma by a single dilution step. Methods Enzymol. 2004;378:170-6. Review. [ Links ]
29. Okamoto T, Fukunaga Y, Ida Y, Kishi T. Determination of reduced and total ubiquinones in biological materials by liquid chromatography with electrochemical detection. J Chromatogr. 1988;430(1):11-9. [ Links ]
30. Kommuru TR, Khan MA, Ashraf M, Kattenacker R, Reddy IK. A simplified chromatographic method for quantitative determination of coenzyme Q10 in dog plasma. J Pharm Biomed Anal. 1998;16(6):1037-40. [ Links ]
31. Takada M, IKenoya S,Yuzuriha T, Katayama K. Simultaneous determination of reduced and oxidezed coenzyme Q10 in human plasma. Methods Enzymol. 1984;105:147-55. [ Links ]
32. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem. 1997;250(1):66-73. [ Links ]
33. Wang Q, Lee BL, Ong CN. Automated high-performance liquid chromatographic method with precolumn reduction for the determination of ubiquinol and ubiquinone in human plasma. J Chromatogr B Biomed Sci Appl. 1999;726(1-2):297-302. [ Links ]
34. Karpińska J, Mikołuć B, Motkowski R, Piotrowska-Jastrzebska J. HPLC method for simultaneous determination of retinol, alpha-tocopherol and coenzyme Q10 in human plasma. J Pharm Biomed Anal. 2006;42(2):232-6. [ Links ]
35. Alleva R, Tomasetti M, Bompadre S, Littarru GP. Oxidation of LDL and their subfractions: kinetic aspects and CoQ10 content. Mol Aspects Med. 1997;18 Suppl:S105-12. [ Links ]
36. Menke T, Niklowitz P, de Sousa G, Reinehr T, Andler W. Comparison of coenzyme Q10 plasma levels in obese and normal weight children. Clin Chim Acta. 2004;349(1-2):121-7. [ Links ]
37. Hirota K, Kawase M, Kishie T. Effect of sodium dodecyl sulphate on the extraction of ubiquinone-10 in the determination of plasma samples. J Chromatogr. 1984;310(1):204-7. [ Links ]
38. González-Mañas JM, Virto MD, Gurtubay JI, Goñi FM. The interaction of Triton X-100 with purple membranes. Detergent binding, spectral changes and membrane solubilization.Eur J Biochem. 1990;188(3):673-8. [ Links ]
Claudia Cristina Ferreiro-Barros
Avenida Albert Einstein, 627 Morumbi
Zip code: 05651-901 São Paulo (SP) Brazil
Received on: Sep 5, 2011
Accepted on: May 28, 2012
Conflict of interest: none.
Study carried out at Instituto do Cérebro InCe, Hospital Israelita Albert Einstein HIAE, São Paulo, Brazil.